Dáil Éireann Debate, Tuesday - 17 May 2016
736. Deputy Seán Crowe asked the Minister for Health if the Health Products Regulatory Authority, formerly the Irish Medicines Board, and the Health Service Executive had the known evidence of toxicity of mefloquine, the full phase III clinical mass trial results and the longitudinal study results for toxicity in targeted market anti-immune population studies on side effects of mefloquine toxicity prior to licensing it in 1989. [9875/16]
View answerThe Health Products Regulatory Authority (HPRA) has indicated that it will take a number of weeks to retrieve and review the information requested by the Deputy. The HPRA will provide the information to the Deputy as soon as possible.
This question has also been referred to the Health Service Executive (HSE) for direct reply to the Deputy. If you have not received a reply from the HSE within 15 working days, please contact my Private office and they will follow up the matter with them.
